ecrin-mdr-crcClinical2017Colorectal cancerColorectal CancerObservationalhttps://newmdr.ecrin.org/Study/2642323Japan6ECRIN MDRCompletedfalseThe optimal cut off value of KRAS testing for the selection of unresectable colorectal cancer patients more likely to benefit from treatment with anti-EGFR in the first line setting.Primary outcome(s): Progression-free survival (PFS)2017-06-152642323JPRN-UMIN000027108